News Tibsovo Approval Expanded for Newly Diagnosed IDH1-Mutated AML By Diana Ernst, RPh Publish Date May 26, 2022
Drugs in the Pipeline Mirvetuximab Soravtansine Granted Priority Review for Ovarian Cancer By Diana Ernst, RPh Publish Date May 23, 2022
Drugs in the Pipeline Tasquinimod Gets Orphan Drug Designation for Myelofibrosis By Brian Park, PharmD Publish Date May 18, 2022
ATS 2022 Do Veterans Receive Lung Cancer Screening at Recommended Intervals? By Pam Brick Publish Date May 16, 2022
Drugs in the Pipeline Trial Evaluating Tiragolumab Combo in PD-L1 High NSCLC Misses PFS Endpoint By Brian Park, PharmD Publish Date May 11, 2022
Drugs in the Pipeline April 2022: Drug Pipeline Updates By Brian Park, PharmD Publish Date May 9, 2022
News Enhertu Approval Broadens Breast Cancer Indication to Earlier Use By Diana Ernst, RPh Publish Date May 5, 2022
News FDA Clears Automated, Wearable 3D Breast Ultrasound Device By Brian Park, PharmD Publish Date May 4, 2022
Drugs in the Pipeline Darolutamide Plus Docetaxel Gets Priority Review for Metastatic Hormone-Sensitive Prostate Cancer By Brian Park, PharmD Publish Date May 3, 2022
Drugs in the Pipeline Enhertu Designated Breakthrough Therapy for HER2-Low Metastatic Breast Cancer By Diana Ernst, RPh Publish Date April 27, 2022
News COVID-19 mRNA Vaccine Efficacy Wanes Over Time in RCC Cases By Natasha Persaud Publish Date April 26, 2022
Drugs in the Pipeline Combo Immunotherapy Gets Priority Review for Advanced Liver Cancer By Diana Ernst, RPh Publish Date April 25, 2022
News Ivosidenib Plus Azacitidine Meet Endpoints in IDH1-Mutated AML Trial By Brian Park, PharmD Publish Date April 22, 2022